Publications 2024

Angeles MA, Agusti N, Bonaldo G, Bizzarri N, Bilir E, Piedimonte S, Olearo E, Navarro Santana B, Sahin Aker S, El Hajj H, Ghirardi V, Kacperczyk-Bartnik J, Strojna AN, Fotopoulou C, Plante M, Lorusso D, Cibula D, Lindemann K, Scambia G, McCormack M, Leitao M, Fagotti A, Concin N, Martinez A, Ramirez PT (2024)
Highlights from the 25th European Congress on Gynaecological Oncology in Barcelona: the ENYGO-IJGC Fellow Interviews
Int J Gynecol Cancer, 34 (10), 1522-1528
DOI 10.1136/ijgc-2024-005704, PubMed 39181697

Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S (2024)
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
J Immunother Cancer, 12 (4)
DOI 10.1136/jitc-2023-008179, PubMed 38604812

Cun HT, Bernard L, Lande KT, Lawson BC, Nesbakken AJ, Davidson B, Lindemann K, Fellman B, Sørlie T, Soliman PT, Eriksson AGZ (2024)
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma
Gynecol Oncol, 189, 138-145
DOI 10.1016/j.ygyno.2024.07.677, PubMed 39126895

Davidson B, Holth A, Lindemann K, Zahl Eriksson AG, Nilsen TA, Torgunrud A (2024)
Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
Virchows Arch (in press)
DOI 10.1007/s00428-024-03821-9, PubMed 38733380

Davidson B, Teien Lande K, Nebdal D, Nesbakken AJ, Holth A, Lindemann K, Zahl Eriksson AG, Sørlie T (2024)
Endometrial carcinomas with ambiguous histology often harbor TP53 mutations
Virchows Arch (in press)
DOI 10.1007/s00428-024-03912-7, PubMed 39235515

Denschlag D, Heitz F, Pfisterer J, Tutschkow D, Reuss A, Meier W, Harter P, Wimberger P, Mirza MR, Ray-Coquard I, Scambia G, Kim JW, Colombo N, Oaknin A, Sehouli J, Lindemann K, Lebreton C, Eichbaum M, Spiegelberg S, Woopen H, du Bois A (2024)
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
Int J Gynecol Cancer (in press)
DOI 10.1136/ijgc-2024-005663, PubMed 39322609

Kleppe A, Lindemann K, Kildal W, Tobin KAR, Pradhan M, Vlatkovic L, Isaksen MX, Danielsen HE, Askautrud HA, Kristensen GB (2024)
Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer
Gynecol Oncol, 192, 80-88 (in press)
DOI 10.1016/j.ygyno.2024.11.005, PubMed 39549540

Krakstad C, Berg HF, Lindemann K, Halle MK (2024)
Frequency of ERBB2-Low Expression in Endometrial Cancer
JAMA Oncol (in press)
DOI 10.1001/jamaoncol.2024.3660, PubMed 39235791

Lindemann K, Kildal W, Kleppe A, Tobin KAR, Pradhan M, Isaksen MX, Vlatkovic L, Danielsen HE, Kristensen GB, Askautrud HA (2024)
Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer
Eur J Cancer, 200, 113584
DOI 10.1016/j.ejca.2024.113584, PubMed 38330767

Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejía F, Helpman L, Akıllı H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Colombo N, Chang CL, Bednarikova M, Zhu H, Oaknin A et al. (2024)
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet, 404 (10460), 1321-1332
DOI 10.1016/S0140-6736(24)01808-7, PubMed 39288779

Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A et al. (2024)
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Lancet, 403 (10434), 1341-1350
DOI 10.1016/S0140-6736(24)00317-9, PubMed 38521086

Luijten MMW, van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, Boll D, Werner HMJ, van Lonkhuijzen LRCW, Yigit R, Krakstad C, Witteveen PO, Galaal K, van Ginkel AA, Bignotti E, Weinberger V, Sweegers S, Eriksson AGZ, Keizer DM, van de Stolpe A, Romano A, Pijnenborg JMA, European Network For Individualized Treatment In Endometrial Cancer (2024)
Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
Cancers (Basel), 16 (11)
DOI 10.3390/cancers16112084, PubMed 38893205

Mirza MR, Tandaric L, Henriksen JR, Mäenpää J, Christensen RD, Waldstrøm M, Lindemann K, Roed H, Auranen A, Akslen LA, Thomsen LCV, Lindberg SN, Madsen K, Bjørge L (2024)
NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer
Gynecol Oncol, 188, 103-110
DOI 10.1016/j.ygyno.2024.06.017, PubMed 38943691

Os SS, Skipar K, Skovlund E, Hompland I, Hellebust TP, Guren MG, Lindemann K, Nakken ES (2024)
Survival prediction in patients with gynecological cancer irradiated for brain metastases
Acta Oncol, 63, 206-212
DOI 10.2340/1651-226X.2023.34899, PubMed 38647023

Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
Acta Oncol, 63, 379-384
DOI 10.2340/1651-226X.2024.28322, PubMed 38779911

Sehouli J, Boer J, Brand AH, Oza AM, O'Donnell J, Bennett K, Glaspool R, Lee CK, Ethier JL, Harter P, Seebacher-Shariat V, Chang TC, Cohen PA, van Gorp T, Chavez-Blanco A, Welch S, Hranovska H, O'Toole S, Lok CAR, Madariaga A, Rauh-Hain JA, Perez Fidalgo A, Tan D, Michels J, Pothuri B et al. (2024)
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting
Int J Gynecol Cancer, 34 (11), 1677-1684
DOI 10.1136/ijgc-2024-005982, PubMed 39496422

Skipar K, Hompland T, Lund KV, Lindemann K, Hellebust TP, Bruheim K, Lyng H (2024)
MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy
Radiother Oncol, 195, 110263
DOI 10.1016/j.radonc.2024.110263, PubMed 38556173

Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J et al. (2024)
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
Ann Oncol, 35 (11), 968-980
DOI 10.1016/j.annonc.2024.08.2242, PubMed 39284383

Publications 2023

Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N, Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee (2023)
FIGO staging of endometrial cancer: 2023
Int J Gynaecol Obstet, 162 (2), 383-394
DOI 10.1002/ijgo.14923, PubMed 37337978

Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N, Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee (2023)
FIGO staging of endometrial cancer: 2023
J Gynecol Oncol, 34 (5), e85
DOI 10.3802/jgo.2023.34.e85, PubMed 37593813

Concin N, Matias-Guiu X, Fotopoulou C, Creutzberg C, Mutch D, Gaffney D, Lindemann K, Kehoe S, Berek JS, FIGO Committee on Women's Cancer (2023)
Response: FIGO staging of endometrial cancer 2023
Int J Gynaecol Obstet, 164 (1), 369-372
DOI 10.1002/ijgo.15277, PubMed 38055215

Corbaux P, You B, Glasspool RM, Yanaihara N, Tinker AV, Lindemann K, Ray-Coquard IL, Mirza MR, Subtil F, Colomban O, Péron J, Karamouza E, McNeish I, Kelly C, Kagimura T, Welch S, Lewsley LA, Paoletti X, Cook A (2023)
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
Eur J Cancer, 191, 112966
DOI 10.1016/j.ejca.2023.112966, PubMed 37542936

Davidson B, Skeie-Jensen T, Holth A, Lindemann K, Toralba Barrameda AM, Lie AK, Wang Y (2023)
Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma
Virchows Arch, 484 (6), 951-963
DOI 10.1007/s00428-023-03670-y, PubMed 37843640

Dos Santos MV, Holth A, Lindemann K, Staff AC, Davidson B (2023)
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma
Gynecol Oncol, 176, 76-81
DOI 10.1016/j.ygyno.2023.07.004, PubMed 37478615

Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S (2023)
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Clin Cancer Res, 29 (9), 1698-1707
DOI 10.1158/1078-0432.CCR-22-2032, PubMed 36595569

Lindemann K, Heimisdottir Danbolt S, Ramberg L, Eyjólfsdóttir B, Wang YY, Heli-Haugestøl AG, Walcott SL, Mjåland O, Navestad GA, Hermanrud S, Juul-Hansen KE, Bragstad LK, Opheim R, Kleppe A, Kongsgaard U (2023)
Patient-reported nausea after implementation of an enhanced recovery after surgery protocol for gynae-oncology patients
Int J Gynecol Cancer, 33 (8), 1287-1294
DOI 10.1136/ijgc-2023-004356, PubMed 37451689

Lindemann K, Kleppe A, Eyjólfsdóttir B, Heimisdottir Danbolt S, Wang YY, Heli-Haugestøl AG, Walcott SL, Mjåland O, Navestad GA, Hermanrud S, Juul-Hansen KE, Kongsgaard U (2023)
Prospective evaluation of an enhanced recovery after surgery (ERAS) pathway in a Norwegian cohort of patients with suspected or advanced ovarian cancer
Int J Gynecol Cancer, 33 (8), 1279-1286
DOI 10.1136/ijgc-2023-004355, PubMed 37451690

Lundberg FE, Stensheim H, Ullenhag GJ, Sahlgren HM, Lindemann K, Fredriksson I, Johansson ALV (2023)
Risk factors for the increasing incidence of pregnancy-associated cancer in Sweden - a population-based study
Acta Obstet Gynecol Scand, 103 (4), 669-683
DOI 10.1111/aogs.14677, PubMed 37694965

Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ et al. (2023)
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
N Engl J Med, 388 (23), 2145-2158
DOI 10.1056/NEJMoa2216334, PubMed 36972026

Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C et al. (2023)
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Lancet, 403 (10421), 31-43
DOI 10.1016/S0140-6736(23)02405-4, PubMed 38048793

Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mądry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A, OReO/ENGOT-ov38 investigators (2023)
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
Ann Oncol, 34 (12), 1152-1164
DOI 10.1016/j.annonc.2023.09.3110, PubMed 37797734

Skaali T, Blomhoff R, Lindemann K, Smeland S, Bruheim K, Seland M, Thorsen L (2023)
Self-reported distress and problems after treatment for gynecological cancer - Correlation between a short screening tool and longer measures of anxiety/depression and health-related quality of life
Acta Obstet Gynecol Scand, 103 (2), 387-395
DOI 10.1111/aogs.14709, PubMed 37991142

Valstad H, Eyjolfsdottir B, Wang Y, Kristensen GB, Skeie-Jensen T, Lindemann K (2023)
Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome - A single center retrospective analysis
Eur J Surg Oncol, 49 (9), 106958
DOI 10.1016/j.ejso.2023.06.010, PubMed 37349160

Vilming B, Fallås Dahl J, Bentzen AG, Ingebrigtsen VA, Berge Nilsen E, Vistad I, Dørum A, Solheim O, Bjørge L, Zucknick M, Aune G, Lindemann K (2023)
Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer
Int J Gynecol Cancer, 33 (12), 1898-1905
DOI 10.1136/ijgc-2023-004484, PubMed 38000795

Publications 2022

Gatius S, Velasco A, Varela M, Cuatrecasas M, Jares P, Setaffy L, Bonhomme B, Santon A, Lindemann K, Croce S, Davidson B, Lax S, Palacios J, Matias-Guiu X (2022)
Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study
Virchows Arch, 480 (5), 1031-1039
DOI 10.1007/s00428-022-03291-x, PubMed 35124717

Kurnit KC, Nobre SP, Fellman BM, Iglesias DA, Lindemann K, Jhingran A, Eriksson AGZ, Ataseven B, Glaser GE, Mueller JJ, Westin SN, Soliman PT (2022)
Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study
Gynecol Oncol, 167 (3), 452-457
DOI 10.1016/j.ygyno.2022.09.025, PubMed 36243601

Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, Ekmann-Gade AW, Haltia UM, Hansen J, Haug AJ, Høgdall C, Korach J, Lassus H, Lindemann K, Van Nieuwenhuysen E, Ottevanger PB, Polterauer S, Schnack TH (2022)
Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)
Cancer, 128 (16), 3080-3089
DOI 10.1002/cncr.34350, PubMed 35714310

Paulsen T, Liland H, Myklebust TÅ, Lindemann K (2022)
Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study
Int J Gynecol Cancer, 32 (2), 181-188
DOI 10.1136/ijgc-2021-002898, PubMed 34987096

Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E (2022)
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
Gynecol Oncol, 164 (3), 498-504
DOI 10.1016/j.ygyno.2021.12.025, PubMed 35063276

Siegenthaler F, Lindemann K, Epstein E, Rau TT, Nastic D, Ghaderi M, Rydberg F, Mueller MD, Carlson J, Imboden S (2022)
Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification
Gynecol Oncol, 165 (2), 230-238
DOI 10.1016/j.ygyno.2022.02.024, PubMed 35277281

Skipar K, Hompland T, Lund KV, Løndalen A, Malinen E, Kristensen GB, Lindemann K, Nakken ES, Bruheim K, Lyng H (2022)
Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer
Radiother Oncol, 176, 17-24
DOI 10.1016/j.radonc.2022.09.002, PubMed 36113778

Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
A national precision cancer medicine implementation initiative for Norway
Nat Med, 28 (5), 885-887
DOI 10.1038/s41591-022-01777-4, PubMed 35513529

Utne I, Stokke K, Ritchie C, Løyland B, Grov EK, Rasmussen HL, Lindemann K, Paul SM, Torstveit AH, Miaskowski C (2022)
Changes in Subjective Measures of Cognitive Function in Older Adults From the Initiation Through 12 Months After the Receipt of Chemotherapy
Cancer Nurs, 46 (6), E365-E374
DOI 10.1097/NCC.0000000000001140, PubMed 35781267

Publications 2021

Areklett EW, Fagereng E, Bruheim K, Andersson S, Lindemann K (2021)
Self-reported cognitive impairment in cervical cancer survivors: A cross-sectional study
Psychooncology, 31 (2), 298-305
DOI 10.1002/pon.5818, PubMed 34516040

Kargo AS, Jensen PT, Lindemann K, Hjollund NHI, Lund B, Haee M, Möller S, Hansen DG, Dahl Steffensen K (2021)
The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness
Acta Oncol, 60 (4), 434-443
DOI 10.1080/0284186X.2021.1891281, PubMed 33651647

Kargo AS, Jensen PT, Lindemann K, Hjøllund NH, Liposits GI, Raaschou-Jensen N, Knudsen BM, Möller S, Hansen DG, Steffensen KD (2021)
Association of patient-reported outcomes and ovarian cancer recurrence
Int J Gynecol Cancer, 31 (9), 1248-1259
DOI 10.1136/ijgc-2021-002550, PubMed 34489355

Kasius JC, Pijnenborg JMA, Lindemann K, Forsse D, van Zwol J, Kristensen GB, Krakstad C, Werner HMJ, Amant F (2021)
Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification
Cancers (Basel), 13 (22)
DOI 10.3390/cancers13225848, PubMed 34831000

Lindemann K (2021)
Medical treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 31 1, 20

Lindemann K (2021)
Medical treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 31 2, 18

Lindemann K, Smogeli E, Småstuen MC, Bruheim K, Trovik J, Nordberg T, Kristensen GB, Werner HMJ, Nakken E (2021)
Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer
Cancers (Basel), 13 (6)
DOI 10.3390/cancers13061367, PubMed 33803531

Seland M, Skrede K, Lindemann K, Skaali T, Blomhoff R, Bruheim K, Wisløff T, Thorsen L (2021)
Distress, problems and unmet rehabilitation needs after treatment for gynecological cancer
Acta Obstet Gynecol Scand, 101 (3), 313-322
DOI 10.1111/aogs.14310, PubMed 34964982

Skorstad M, de Rooij BH, Jeppesen MM, Bergholdt SH, Ezendam NPM, Bohlin T, Jensen PT, Lindemann K, van de Poll L, Vistad I (2021)
Self-management and adherence to recommended follow-up after gynaecological cancer: results from the international InCHARGE study
Int J Gynecol Cancer, 31 (8), 1106-1115
DOI 10.1136/ijgc-2020-002377, PubMed 33858949

Utne I, Løyland B, Grov EK, Rasmussen HL, Torstveit AH, Paul SM, Ritchie C, Lindemann K, Vistad I, Rodríguez-Aranda C, Miaskowski C (2021)
Age-related differences in self-report and objective measures of cognitive function in older patients prior to chemotherapy
Nurs Open, 9 (2), 1040-1051
DOI 10.1002/nop2.1141, PubMed 34878233

van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, Boll D, Werner HMJ, van Lonkhuijzen LRCW, Yigit R, Forsse D, Witteveen PO, Galaal K, van Ginkel A, Bignotti E, Weinberger V, Sweegers S, Kroep JR, Cabrera S, Snijders MPLM, Inda MA, Eriksson AGZ, European Network for Individualized Treatment in Endometrial Cancer, Krakstad C, Romano A et al. (2021)
Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer
Am J Obstet Gynecol, 225 (4), 407.e1-407.e16
DOI 10.1016/j.ajog.2021.05.007, PubMed 34019887

Vistad I, Skorstad M, Demmelmaier I, Småstuen MC, Lindemann K, Wisløff T, van de Poll-Franse LV, Berntsen S (2021)
Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking
BMJ Open, 11 (7), e050930
DOI 10.1136/bmjopen-2021-050930, PubMed 34253678

Publications 2020

Harter P, Pautier P, Van Nieuwenhuysen E, Reuss A, Redondo A, Lindemann K, Kurzeder C, Petru E, Heitz F, Sehouli J, Degregorio N, Wimberger P, Burges A, Cron N, Ledermann J, Lorusso D, Paoletti X, Marme F (2020)
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
Int J Gynecol Cancer, 30 (12), 1997-2001
DOI 10.1136/ijgc-2020-001572, PubMed 32606097

Kargo AS, Coulter A, Lindemann K, Jensen PT, Hjøllund NH, Mosgaard BJ, Steffensen KD (2020)
Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol
Int J Gynecol Cancer, 30 (9), 1444-1449
DOI 10.1136/ijgc-2020-001528, PubMed 32586892

La Russa M, Zapardiel I, Zalewski K, Laky R, Dursun P, Sukhin V, Lindquist D, Lindemann K (2020)
Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members
BMJ Support Palliat Care (in press)
DOI 10.1136/bmjspcare-2020-002233, PubMed 32958506

Lindemann K (2020)
Systematic treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 30 1, 15

Lindemann K, Martinsson L, Kaasa S, Lindquist D (2020)
Elderly gynaecological cancer patients at risk for poor end of life care: a population-based study from the Swedish Register of Palliative Care
Acta Oncol, 59 (6), 636-643
DOI 10.1080/0284186X.2020.1744717, PubMed 32238040

Vistad I, Lindemann K, Bentzen AG, Dahl AA, Steen R, Kiserud C (2020)
Preferences for follow up in long-term survivors after cervical cancer
Acta Obstet Gynecol Scand, 99 (9), 1253-1259
DOI 10.1111/aogs.13855, PubMed 32232835

Publications 2019

Lindemann K, Zalewski K, Halaska MJ (2019)
Summary of landmark papers published between August 2018 and May 2019
Int. J. Gynecol. Cancer, 29 1, 1-5
DOI 10.1136/ijgc-2019-000738

Piovano E, Ferrero A, Zola P, Marth C, Mirza MR, Lindemann K (2019)
Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects
Int J Gynecol Cancer, 29 (1), 181-187
DOI 10.1136/ijgc-2018-000021, PubMed 30640702

Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L (2019)
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
Cochrane Database Syst Rev, 10 (10), CD012160
DOI 10.1002/14651858.CD012160.pub2, PubMed 31588998

Publications 2018

Lindemann K (2018)
Medical treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 28 4, 29

Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin E, Lavranos TC, Leske A, Veillard AS, Espinoza D, Stockler MR, Rischin D, For ANZGOG and HCRN Collaborative Groups (2018)
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
Cancer Chemother Pharmacol, 83 (1), 97-105
DOI 10.1007/s00280-018-3706-5, PubMed 30368585

Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DDL, deFazio A (2018)
Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
Gynecol Oncol, 150 (2), 239-246
DOI 10.1016/j.ygyno.2018.05.020, PubMed 29807697

Lindemann K, Zalewski K, Halaska MJ, Lindquist D (2018)
PREFACE
Int. J. Gynecol. Cancer, 28 4, 2

Smogeli E, Cvancarova M, Wang Y, Davidson B, Kristensen G, Lindemann K (2018)
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
Int J Gynecol Cancer, 28 (9), 1789-1795
DOI 10.1097/IGC.0000000000001356, PubMed 30365455

Publications 2017

Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G (2017)
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
Br J Cancer, 116 (4), 455-463
DOI 10.1038/bjc.2016.435, PubMed 28118323

Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A (2017)
Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed
Int J Gynecol Cancer, 27 (6), 1274-1282
DOI 10.1097/IGC.0000000000000981, PubMed 28498237

Lindemann K, Kok PS, Stockler M, Sykes P, Brand A (2017)
Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial
Int J Gynecol Cancer, 27 (5), 1046-1050
DOI 10.1097/IGC.0000000000000982, PubMed 28525497

Minig L, Heitz F, Cibula D, Bakkum-Gamez JN, Germanova A, Dowdy SC, Kalogera E, Zapardiel I, Lindemann K, Harter P, Scambia G, Petrillo M, Zorrero C, Zanagnolo V, Rebollo JMC, du Bois A, Fotopoulou C (2017)
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
Ann Surg Oncol, 24 (9), 2720-2726
DOI 10.1245/s10434-017-5919-y, PubMed 28608122

Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2017)
The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study
Neuro Oncol, 19 (7), 976-985
DOI 10.1093/neuonc/now272, PubMed 28040713

Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2017)
Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study
Acta Oncol, 56 (10), 1302-1309
DOI 10.1080/0284186X.2017.1330554, PubMed 28548875

Zalewski K, Lindemann K, Halaska MJ, Zapardiel I, Laky R, Chereau E, Lindquist D, Polterauer S, Sukhin V, Dursun P (2017)
A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists
Int J Gynecol Cancer, 27 (3), 620-626
DOI 10.1097/IGC.0000000000000917, PubMed 28187096

Publications 2016

Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A (2016)
Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome
Gynecol Oncol, 142 (3), 458-64
DOI 10.1016/j.ygyno.2016.06.023, PubMed 27444035

Lindemann K (2016)
Medical treatment of primary or recurrent cervical cancer
Int. J. Gynecol. Cancer, 26 1, 42-43

Lindemann K, Halaska MJ, Zalewski K (2016)
Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
Int. J. Gynecol. Cancer, 26 1, 5-8

Lindemann K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, Ayhan A, Burges A, Rubio MJ, Raspagliesi F, Huizing M, Creemers GJ, Lykka M, Lee CK, Gebski V, Pujade-Lauraine E (2016)
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
Ann Oncol, 27 (8), 1505-10
DOI 10.1093/annonc/mdw238, PubMed 27407100

Lindemann K, Zalewski K, Halaska MJ, LiFE Team (2016)
Preface
Int. J. Gynecol. Cancer, 26 1, 2

Lindemann K, Zalewski K, Halaska MJ, Lindquist D, The LiFE Team (2016)
Life - Literature for ENYGO
Int. J. Gynecol. Cancer, 26 4, 2-73

Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K (2016)
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
BMC Cancer, 16, 596
DOI 10.1186/s12885-016-2631-4, PubMed 27488577

Zalewski K, Lindemann K, Halaska MJ (2016)
Medical treatment of primary ovarian cancer
Int. J. Gynecol. Cancer, 26 1, 9-11

Publications 2015

Lindemann K, Cvancarova M, Eskild A (2015)
Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey
Gynecol Oncol, 139 (3), 476-80
DOI 10.1016/j.ygyno.2015.09.088, PubMed 26434365

Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2015)
Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study)
Eur J Epidemiol, 31 (1), 95-8
DOI 10.1007/s10654-015-0033-6, PubMed 25903163

Publications 2014

Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrøm B (2014)
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
BMC Cancer, 14, 68
DOI 10.1186/1471-2407-14-68, PubMed 24498853

Publications 2013

Onsrud M, Cvancarova M, Hellebust TP, Tropé CG, Kristensen GB, Lindemann K (2013)
Long-term outcomes after pelvic radiation for early-stage endometrial cancer
J Clin Oncol, 31 (31), 3951-6
DOI 10.1200/JCO.2013.48.8023, PubMed 24019546

Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2013)
Body mass index and the risk of meningioma, glioma and schwannoma in a large prospective cohort study (The HUNT Study)
Br J Cancer, 109 (1), 289-94
DOI 10.1038/bjc.2013.304, PubMed 23778522

Publications 2012

Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB (2012)
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
Ann Oncol, 23 (10), 2613-2619
DOI 10.1093/annonc/mds060, PubMed 22539562

Publications 2011

Rettinger G, Lindemann K, Ashoor M, Scheithauer M, Sommer F, Lindemann J (2011)
[Long term results of transseptal suture of the middle turbinate during sinus surgery]
Laryngorhinootologie, 90 (8), 471-5
DOI 10.1055/s-0031-1280840, PubMed 21809231

Publications 2010

Lindemann K, Eskild A, Vatten LJ, Bray F (2010)
Endometrial cancer incidence trends in Norway during 1953-2007 and predictions for 2008-2027
Int J Cancer, 127 (11), 2661-8
DOI 10.1002/ijc.25267, PubMed 20162667

Publications 2009

Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A (2009)
Serum lipids and endometrial cancer risk: results from the HUNT-II study
Int J Cancer, 124 (12), 2938-41
DOI 10.1002/ijc.24285, PubMed 19267407

Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A (2009)
The impact of BMI on subgroups of uterine cancer
Br J Cancer, 101 (3), 534-6
DOI 10.1038/sj.bjc.6605158, PubMed 19568239

Publications 2008

Lindemann K, Harbeck N, Lengyel E, Resau JH (2008)
A special key for unlocking the door to targeted therapies of breast cancer
ScientificWorldJournal, 8, 905-8
DOI 10.1100/tsw.2008.110, PubMed 18836657

Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A (2008)
Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study
Br J Cancer, 98 (9), 1582-5
DOI 10.1038/sj.bjc.6604313, PubMed 18362938

Publications 2007

Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N (2007)
Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue
Histopathology, 51 (1), 54-62
DOI 10.1111/j.1365-2559.2007.02732.x, PubMed 17593080

Publications 2005

Janni W, Rack B, Lindemann K, Harbeck N (2005)
Detection of micrometastatic disease in bone marrow: is it ready for prime time?
Oncologist, 10 (7), 480-92
DOI 10.1634/theoncologist.10-7-480, PubMed 16079315

Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N (2005)
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
Int J Cancer, 113 (4), 678-82
DOI 10.1002/ijc.20598, PubMed 15455388